Drug intelligence / Profile preview

HM-001

Development stage: Unknown
Lead developer: HOIST
Modality: Small Molecules
Administration: Intravesical, Intraperitoneal

Overview

HM-001 is a small molecule therapeutic based on the Matching Transformation (MA-T) system, developed by HOIST. The MA-T system utilizes sodium chlorite to generate reactive oxygen species (aqueous radicals) specifically within the acidic microenvironment of tumors. This localized activation is intended to exert potent antitumor effects while minimizing systemic toxicity. HM-001 is currently being evaluated in a Phase 1/2 investigator-initiated clinical trial for the treatment of non-muscle invasive bladder cancer (NMIBC) at Osaka University Hospital. It is also in preclinical development for peritoneal carcinomatosis associated with gastrointestinal and gynecological cancers, including colon, ovarian, and pancreatic cancers.

Other names: MA-T system

Targets

PS (Phosphatidylserine)

Beyond the preview

Go deeper on HM-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HM-001.

Explore the full profile